| Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci FR Schumacher, AA Al Olama, SI Berndt, S Benlloch, M Ahmed, ... Nature genetics 50 (7), 928-936, 2018 | 770 | 2018 |
| Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation APM Finch, J Lubinski, P Møller, CF Singer, B Karlan, L Senter, B Rosen, ... Journal of Clinical Oncology 32 (15), 1547, 2014 | 704 | 2014 |
| Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array RA Eeles, AAA Olama, S Benlloch, EJ Saunders, DA Leongamornlert, ... Nature genetics 45 (4), 385-391, 2013 | 669 | 2013 |
| Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer SE Bojesen, KA Pooley, SE Johnatty, J Beesley, K Michailidou, JP Tyrer, ... Nature genetics 45 (4), 371-384, 2013 | 646 | 2013 |
| CHEK2 is a multiorgan cancer susceptibility gene C Cybulski, B Gorski, T Huzarski, B Masojć, M Mierzejewski, T Dębniak, ... The American Journal of Human Genetics 75 (6), 1131-1135, 2004 | 619 | 2004 |
| Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer TR Rebbeck, N Mitra, F Wan, OM Sinilnikova, S Healey, L McGuffog, ... Jama 313 (13), 1347-1361, 2015 | 547 | 2015 |
| A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer AA Al Olama, Z Kote-Jarai, SI Berndt, DV Conti, F Schumacher, Y Han, ... Nature genetics 46 (10), 1103-1109, 2014 | 521 | 2014 |
| Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients T Byrski, T Huzarski, R Dent, J Gronwald, D Zuziak, C Cybulski, J Kladny, ... Breast cancer research and treatment 115, 359-363, 2009 | 457 | 2009 |
| GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer PDP Pharoah, YY Tsai, SJ Ramus, CM Phelan, EL Goode, K Lawrenson, ... Nature genetics 45 (4), 362-370, 2013 | 416 | 2013 |
| A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general … AC Antoniou, X Wang, ZS Fredericksen, L McGuffog, R Tarrell, ... Nature genetics 42 (10), 885-892, 2010 | 406 | 2010 |
| Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients T Byrski, T Huzarski, R Dent, E Marczyk, M Jasiówka, J Gronwald, ... Breast cancer research and treatment 147, 401-405, 2014 | 339 | 2014 |
| Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study Z Kote-Jarai, AAA Olama, GG Giles, G Severi, J Schleutker, M Weischer, ... Nature genetics 43 (8), 785-791, 2011 | 332 | 2011 |
| Risk of Breast Cancer in Women With a CHEK2 Mutation With and Without a Family History of Breast Cancer C Cybulski, D Wokołorczyk, A Jakubowska, T Huzarski, T Byrski, ... Journal of Clinical Oncology 29 (28), 3747-3752, 2011 | 311 | 2011 |
| Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction DV Conti, BF Darst, LC Moss, EJ Saunders, X Sheng, A Chou, ... Nature genetics 53 (1), 65-75, 2021 | 308 | 2021 |
| Identification of six new susceptibility loci for invasive epithelial ovarian cancer KB Kuchenbaecker, SJ Ramus, J Tyrer, A Lee, HC Shen, J Beesley, ... Nature genetics 47 (2), 164-171, 2015 | 307 | 2015 |
| Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study EK Bancroft, EC Page, E Castro, H Lilja, A Vickers, D Sjoberg, M Assel, ... European urology 66 (3), 489-499, 2014 | 290 | 2014 |
| A high proportion of founder BRCA1 mutations in Polish breast cancer families B Górski, A Jakubowska, T Huzarski, T Byrski, J Gronwald, E Grzybowska, ... International journal of cancer 110 (5), 683-686, 2004 | 258 | 2004 |
| CA125 and ovarian cancer: a comprehensive review P Charkhchi, C Cybulski, J Gronwald, FO Wong, SA Narod, MR Akbari Cancers 12 (12), 3730, 2020 | 251 | 2020 |
| Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer T Byrski, R Dent, P Blecharz, M Foszczynska-Kloda, J Gronwald, ... Breast cancer research 14, 1-8, 2012 | 240 | 2012 |
| PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS MC Southey, DE Goldgar, R Winqvist, K Pylkäs, F Couch, M Tischkowitz, ... Journal of medical genetics 53 (12), 800-811, 2016 | 238 | 2016 |
